Inventor
Carl-Henrik Heldin
Inventor
Uppsala, SE
Overview
Patents· 41 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C07Kprimary
C07KPeptides30%
A61KPreparations for medical, dental or toiletry purposes24%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations11%
C12NMicroorganisms or enzymes10%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms6%
G01NInvestigating or analysing materials by determining their chemical or physical properties6%
C40BCombinatorial chemistry3%
A01KAnimal husbandry2%
B82YSpecific uses or applications of nanostructures2%
C07HSugars2%
PatentTitleYear
9,296,818'Cleavage inhibitors of transforming growth factor beta type I receptor and uses thereof in cancer therapy'20169,096,901'Methods and materials related to hair pigmentation and cancer'20158,278,043'Methods and materials related to grey alleles'20128,080,639'Antibodies which bind specifically to activin receptor like kinase 3'20117,932,351'Activin receptor-like kinase-1 proteins having serine-threonine kinase domains'20117,723,339'Combination comprising a signal transduction inhibitor and an epothilone derivative'20107,592,428'Antibodies which bind specifically to activin receptor like kinases'20097,148,037'Platelet-derived growth factor D, DNA coding therefor, and uses thereof'20067,141,375'Methods and compositions for treatment of tumors using nucleic acid ligands to platelet-derived growth factor'20067,067,260'Methods of identifying morphogen receptor-binding analogs'20066,982,319'Antibodies which bind specifically to activin receptor-like kinases'20066,974,816'Combination for the treatment of endothelial damage'20056,939,849'Recombinant PDGF A-chain homodimers and methods of use'20056,706,687'Platelet-derived growth factor D'20046,699,843'Method for treatment of tumors using nucleic acid ligands to PDGF'20046,673,570'Smad associating polypeptides'20046,632,618'Morphogenic protein-specific cell surface receptors and uses therefor'20036,605,443'Method for identifying compounds that affect Smad7 binding'20036,475,775'PARG, a GTPase activating protein which interacts with PTPL1'20026,368,829'Smad2 phosphorylation and interaction with Smad4'20026,331,621'Isolated nucleic acid molecules which encode activin-receptor like kinases, expression vectors and cells containing these'20016,316,217'Activin receptor-like kinases, proteins having serine threonine kinase domains and polynucleotides encoding same'20016,271,365'Activin like receptor--Isolated kinase proteins ALK-2, ALK-4, ALK-5, and nucleic acid molecules encoding them'20016,251,628'Isolated nucleic acid molecules encoding Smad7'20016,207,814'Activin receptor-like kinases, ALK-3 and ALK-6, and nucleic acids encoding them'20016,103,869'Smad2 phosphorylation and interaction with Smad4'20006,083,721'Isolated nucleic acid molecules encoding PARG, a GTPase activating protein which interacts with PTPL1'20006,066,472'Nucleic acids coding for GLM-2, a novel protein tyrosine phosphatase'20005,863,738'Methods of antagonizing OP-1 binding to a cell surface receptor utilizing ALK polypeptides'19995,821,075'Nucleotide sequences for novel protein tyrosine phosphatases'19985,756,686'Peptides derived from endothelial cell growth factor'19985,731,200'Isolated nucleic acid encoding receptor-like TGF-.beta.1 binding protein'19985,605,816'Recombinant DNA encoding PDGF A-chain polypeptides'19975,444,151'Platelet derived growth factor antagonists'19955,346,993'Isolated, large latent complexes of TGF-.beta.2 and TGF-.beta.3, and new binding protein for latent form TGF-.beta.1, TGF-.beta.2 and TGF-.beta.3 LTBP-2'19945,326,695'Platelet derived growth factor agonists'19945,280,109'Isolated, large latent complexes of TGF-.beta.2 and TGF-.beta.3, and new binding protein for latent form TGF-.beta.1, TGF-.beta.2 and TGF-.beta.3 LTBP-2'19945,229,495'Substantially pure receptor like TGF-.beta. 1 binding molecules and uses thereof'19935,227,302'DNA encoding platelet derived endothelial cell growth factor (PD-ECGF)'19935,219,759'Recombinant DNA encoding PDGF A-chain polypeptide and expression vectors'19935,177,197'Isolated nucleotide sequence expressing human transforming growth factor-.beta.1-binding protein'1993Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
1993–2011Patents assigned to LUDWIG INST CANCER RES (29)· patent assignee history
1993–2005Patents assigned to CHIRON CORP (3)· patent assignee history
1993–2016Based in Uppsala, SE· patent location history
1993–1999Based in Upsala, SE· patent location history
2003–2006Patents assigned to CURIS INC (2)· patent assignee history
2011–2016Patents assigned to HELDIN CARL-HENRIK (4)· patent assignee history
2012–2015Patents assigned to ANDERSSON LEIF (2)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| LUDWIG INST CANCER RES | 29 | 1993–2011 |
| HELDIN CARL-HENRIKself | 4 | 2011–2016 |
| CHIRON CORP | 3 | 1993–2005 |
| ANDERSSON LEIF | 2 | 2012–2015 |
| CURIS INC | 2 | 2003–2006 |
Locations
| Location | Patents | Span |
|---|---|---|
| Uppsala, SE | 36 | 1993–2016 |
| Upsala, SE | 5 | 1993–1999 |